NEW YORK (GenomeWeb) – A group that evaluates the cost- and comparative-effectiveness of drugs is turning its attention to precision treatments for advanced non-small cell lung cancer, aiming to come up with a "fair" price for them.
Premium Access gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.